The companies and brands that innovate in anticipation of the impact of these drugs will find themselves awash in new interest from those who feel a new sense of control and autonomy in their choices: brands that speak to their aspirational selves, affirm their commitments to living better, and underscore that behavior-modifying medications are only step one of a lifelong shift that includes their category and brand
The single most common source of disappointment with a compound like KLOW is expecting a fast, dramatic, visible change
The more muscle mass an individual has, the higher their resting metabolic rate, which is the number of calories the body burns at rest
In the United States, obesity rates are not evenly distributed.States across the American South and Midwest consistently report some of the highest obesity prevalence
We also employed a self-controlled case series design to compare suicide, or suicide attempts before and after GLP-1 RA treatment initiation across three time periods
fMRI in human studies showed GLP-1R agonists reduce neural response to food cues in reward circuits (40% striatal activation) within 2 weeks of treatment